The European Medicines Evaluation Agency’s scientific committee (CPMP) is expected to rule this week whether calcitonins are effective in the treatment of osteoporosis, industry sources said on Monday.
Although this is an old, well-established drug, the conditions it is licensed to treat vary from country to country. In parts of Europe it is indicated for post-menopausal osteoporosis, while elsewhere it is indicated for other conditions such as Paget’s disease.
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!